LYCOS RETRIEVER 
Remicade: Treatments
built 654 days ago
Remicade treatment has been previously linked to serious side effects, including fatal reactions such as heart failure and infections including tuberculosis, histoplasmosis, listeriosis, and pneumocystosis. The FDA has issued a series of warnings and now requires the drug to carry a special "black box warning" on its label, a heightened warning for potentially dangerous drugs.
Source:
Remicade is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and the only agent approved for the treatment of both rheumatoid arthritis (RA) and Crohn's disease (CD) in North America, the European Union (EU) and Japan. In the EU and in the U.S., Remicade is approved for the treatment of active ankylosing spondylitis (AS) and psoriatic arthritis.
Source:
Remicade is a breakthrough treatment for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). It works quickly to suppress inflammation caused by your immune system. This relieves your symptoms and helps to prevent your RA or AS progressing.
Source:
Remicade was approved for the treatment of Crohn's disease in 1998 and for rheumatoid arthritis in 2000. Since then Centocor says it has learned of several reports of blood and nervous system disorders, including some fatal cases, in people taking the drug.
Source:
Update: On Sept. 27, 2006, Remicade was approved for the treatment of severe plaque psoriasis. An update to this fact sheet to reflect this approval is forthcoming. Read more about the psoriasis approval.
Source:
When Centocor, Inc. received FDA approval for its drug Remicade (infliximab) in August of 1998, it was hailed as a breakthrough. Approved for the treatment of rheumatoid arthritis and Crohn's disease, Remicade was studied with hopes to expand its indications.
Source:
MORE ABOUT
Treatments